Cellectis (CLLS) Prices 8.8M ADS Offering at $2.50/ADS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Cellectis Announces Pricing of Follow-On Offering
February 3, 2023 12:48 AM ESTNEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (Cellectis or the Company) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces the pricing of its previously announced underwritten global offering by way of a capital increase of 8,800,000 American Depositary Shares (ADS), each representing the right to receive one ordinary share of Cellectis, nominal value 0.05 per share (the Global Offering), comprised of a public offering of ADS in the United States of America only and a private placement in other countries... More
